Edition:
India

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

1.05USD
12 Dec 2017
Change (% chg)

$-0.02 (-1.87%)
Prev Close
$1.07
Open
$1.07
Day's High
$1.09
Day's Low
$1.05
Volume
56,765
Avg. Vol
141,377
52-wk High
$7.28
52-wk Low
$1.04

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $50.18
Shares Outstanding(Mil.): 28.67
Dividend: --
Yield (%): --

Financials

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

02 Nov 2017

BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

26 Sep 2017

BRIEF-Genocea Biosciences reports qtrly loss per share $‍0.54​

* Genocea Biosciences reports second quarter 2017 financial results

09 Aug 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.55 --
Pfizer Inc. (PFE.N) $36.58 +0.37
Merck & Co., Inc. (MRK.N) $57.07 +0.73
Sanofi SA (SASY.PA) €75.03 --
AstraZeneca plc (AZN.L) 4,935.00 +58.00
GlaxoSmithKline plc (GSK.L) 1,314.50 +11.50
Vical Incorporated (VICL.OQ) $1.78 -0.05

Earnings vs. Estimates